Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

E-ISSN： 1096-8652|90|3|E40-E43

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.3, 2015-03, pp. : E40-E43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of eltrombopag after romiplostim in primary immune thrombocytopenia

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 111-116

John Wiley & Sons Inc

Access to resources Recommend Favorite

Spotlight on Eltrombopag in Treatment-Refractory Chronic Primary Immune Thrombocytopenia†

By Garnock-Jones Karly P.

BioDrugs, Vol. 25, Iss. 6, 2011-12 ,pp. : 401-404

Adis International

Access to resources Recommend Favorite

Eltrombopag: A Review of its Use in Treatment-Refractory Chronic Primary Immune Thrombocytopenia

By Garnock-Jones Karly P.

Drugs, Vol. 71, Iss. 10, 2011-07 ,pp. : 1333-1353

Adis International

Access to resources Recommend Favorite

Usage of Eltrombopag for Chronic Immune Thrombocytopenia as a Pretreatment for Splenectomy

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 45-47

Karger

Access to resources Recommend Favorite

Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 598-601

John Wiley & Sons Inc

Access to resources Recommend Favorite